Powering RCTs for Marginal Effects With GLMs Using Prognostic Score Adjustment
Statistics in Medicine · 2026-04 · 45 (8-9)
DOI: 10.1002/sim.70524 ↗At a glance
Journal article in Statistics in Medicine, published online on 2026-04-08. Written by Emilie Højbjerre-Frandsen and 2 co-authors. Institution: Biostatistics Methods, Novo Nordisk A/S, Søborg, Denmark. Major MEDLINE topics: Randomized Controlled Trials as Topic, Linear Models, Data Interpretation, Statistical, Outcome Assessment, Health Care. 62 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Innovationsfonden.
Abstract (original language)
In randomized clinical trials (RCTs), the accurate estimation of marginal treatment effects is crucial for determining the efficacy of interventions. Enhancing the statistical power of these analyses is a key objective for statisticians. The increasing availability of historical data from registries, prior trials, and health records presents an opportunity to improve trial efficiency. However, many methods for historical borrowing compromise strict type I error rate control. Building on the work by Schuler et al. on prognostic score adjustment for linear models, this paper extends the methodology to the plug‐in analysis proposed by Rosenblum and van der Laan using generalized linear models (GLMs) to further enhance the efficiency of RCT analyses without introducing bias. Specifically, we train a prognostic model on historical control data and incorporate the resulting prognostic scores as covariates in the plug‐in GLM analysis of the trial data. This approach leverages the predictive power of historical data to improve the precision of marginal treatment effect estimates. We demonstrate that this method achieves local semi‐parametric efficiency under the assumption of an additive treatment effect on the link scale. We expand the GLM plug‐in method to include Negative Binomial regression. Additionally, we provide a straightforward formula for conservatively estimating the asymptotic variance, facilitating power calculations that reflect these efficiency gains. Our simulation study supports the theory. Even without an additive treatment effect, we observe increased power or reduced standard error. While population shifts from historical to trial data may dilute benefits, they do not introduce bias. We demonstrate reductions in the estimated variance through an analysis of clinical trial data provided by Novo Nordisk A/S.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Biostatistics Methods, Novo Nordisk A/S, Søborg, Denmark.
- Department of Mathematical Sciences, Aalborg University, Aalborg Øst, Denmark.
- Division of Biostatistics, University of California Berkeley, Berkeley, California, USA.
ORCID profiles: Emilie Højbjerre-Frandsen
Funding
- Innovationsfonden
Cite
APA
Højbjerre-Frandsen, E., van der Laan, M. J., & Schuler, A. (2026). Powering RCTs for Marginal Effects With GLMs Using Prognostic Score Adjustment. Statistics in Medicine, 45(8-9). https://doi.org/10.1002/sim.70524
Vancouver
Højbjerre-Frandsen E, van der Laan MJ, Schuler A. Powering RCTs for Marginal Effects With GLMs Using Prognostic Score Adjustment. Statistics in Medicine. 2026;45(8-9). doi:10.1002/sim.70524
BibTeX
@article{HjbjerreFrandsen2026,
author = {Højbjerre-Frandsen, Emilie and van der Laan, Mark J and Schuler, Alejandro},
title = {Powering RCTs for Marginal Effects With GLMs Using Prognostic Score Adjustment},
journal = {Statistics in Medicine},
year = {2026},
volume = {45},
number = {8-9},
doi = {10.1002/sim.70524}
}
EUVIMED